Reagan Scott

Background: Alopecia areata (AA) is a chronic, relapsing autoimmune condition affecting approximately 2% of the global population, causing nonscarring hair loss with significant psychosocial impact.¹ Despite its prevalence, the immunological mechanisms underlying AA remained poorly defined for decades, and no FDA-approved systemic therapies existed until 2022. AA is now understood to involve collapse of immune privilege at the hair follicle — a site normally protected from immune surveillance — yet the precise effector and regulatory cell populations responsible for this breakdown had not been comprehensively characterized. This review synthesizes evidence from five primary studies to propose a dual-pathway disease model in which hyperactivation of cytotoxic CD8+ T cells converges with failure of tissue-resident regulatory T cells (Tregs) to drive immune privilege collapse and follicular destruction.

Objective: To examine the immunological mechanisms by which CD8+ T cell effector hyperactivity and Treg dysfunction converge on hair follicle immune privilege collapse in alopecia areata, and to evaluate JAK inhibition as clinical validation of this dual-pathway model.

Search Methods: A literature search was conducted in PubMed from 2017 to 2024 using the following MeSH terms and keywords: “alopecia areata,” “CD8 T cells,” “regulatory T cells,” “immune privilege,” “hair follicle,” “JAK inhibitor,” “baricitinib,” “NkG2D,” “virtual memory T cells,” and “FOXP3.”

Results: Single-cell RNA sequencing of AA mouse skin identified CD8+ T cells as the necessary and sufficient effectors, with antibody depletion preventing disease in 15/15 mice, and novel FR4+ Tregs at the hair follicle stem cell niche playing a protective counter-role.¹ Circulating AA patients showed a 47% reduction in CD39+ suppressor Tregs (P=0.001) with absent CD39 protein expression in peripheral blood mononuclear cells, establishing quantitative Treg deficiency as a disease feature.² A virtual memory CD8+ T cell-derived subset (CD44s-hiCD49dlo) was identified as sufficient to independently induce AA through NKG2D-dependent innate-like cytotoxicity driven by IL-12/IL-15/IL-18 bystander activation — a TCR-independent mechanism explaining disease onset without known autoantigens.³ Skin-specific Treg depletion experiments demonstrated that tissue-resident Tregs maintain hair follicle immune privilege via IL-2 consumption through CD25, and spatial transcriptomics of human AA tissue confirmed aberrant IL-2/STAT5 signatures at follicular interfaces.⁴ In the BRAVE-AA1 randomized controlled trial, baricitinib 4mg achieved a SALT score ≤20 in 51.9% of patients versus 3.6% with placebo (P<0.001) at 36 weeks, clinically validating the JAK/STAT cytokine axis as central to AA pathogenesis.⁵

Conclusion: AA pathogenesis reflects dual failure: a hyperactive CD8+ effector arm executing NKG2D-mediated cytotoxicity, and a deficient Treg arm unable to maintain follicular immune privilege through IL-2 and CD39/adenosine pathways. JAK inhibition simultaneously disrupts IFN-γ and IL-15 signaling, validating this integrated model and achieving FDA approval in 2022. Future therapeutic strategies targeting both arms — including IL-2 pathway modulation to restore Treg function and NKG2D blockade to suppress effector cytotoxicity — may improve upon current response rates and reduce relapse risk for patients who do not achieve durable remission with JAK inhibitors alone.

Works Cited

1. Lee EY, Dai Z, Jaiswal A, Wang EHC, Anandasabapathy N, Christiano AM. Functional interrogation of lymphocyte subsets in alopecia areata using single-cell RNA sequencing. Proc Natl Acad Sci U S A. 2023;120(29):e2305764120. doi:10.1073/pnas.2305764120
2. Hamed FN, Åstrand A, Bertolini M, et al. Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCRβ-chain, which highlights the immunopathological aspect of the disease. PLoS One. 2019;14(7):e0210308. doi:10.1371/journal.pone.0210308
3. Seok J, Cho SD, Lee J, et al. A virtual memory CD8+ T cell-originated subset causes alopecia areata through innate-like cytotoxicity. Nat Immunol. 2023;24(8):1308-1317. doi:10.1038/s41590-023-01547-5
4. Cohen JN, Gouirand V, Macon CE, et al. Regulatory T cells in skin mediate immune privilege of the hair follicle stem cell niche. Sci Immunol. 2024;9(91):eadh0152. doi:10.1126/sciimmunol.adh0152
5. King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847-853. doi:10.1016/j.jaad.2021.05.050